Torrent Pharmaceuticals

Torrent Pharmaceuticals

3,550.50
-18.50
(-0.52%)
hide
Key Fundamentals
Add Ratio
Market Cap
1,20,791.20 Cr
EPS
56.47
PE Ratio
59.48
Dividend Yield
0.17 %
Industry
Healthcare
52 Week High
3,787.90
52 Week Low
2,886.45
PB Ratio
15.82
Debt to Equity
0.50
Analyst Rating and Forecast
- By Refinitiv from27 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+70.37 %
+70.37 %
Hold
Hold+25.93 %
+25.93 %
Sell
Sell+3.70 %
+3.70 %
Forecast For
Actual

Company News

View All News
Caret
negative
The Competition Commission of India has raised concerns regarding an agreement between JB Chemicals and Torrent Pharma. The regulatory body's concerns suggest potential competition-related issues with the arrangement between the two pharmaceutical companies.
neutral
Torrent Pharmaceuticals Limited has issued Commercial Papers worth ₹200 crores with a 90-day tenure and 5.93% per annum interest rate. The papers were allotted on September 24, 2025, with maturity date of December 23, 2025. The Commercial Papers are unsecured and proposed to be listed on the National Stock Exchange of India. Interest payment is scheduled upfront, while principal payment will be made on maturity.
positive
Torrent Pharmaceuticals Limited has received approval from the Competition Commission of South Africa for its acquisition of a controlling stake in J.B. Chemicals & Pharmaceuticals from KKR. The approval was granted on September 22, 2025. This follows the initial media release about the acquisition dated June 29, 2025. The company stated it is committed to continuing relationships with all customers on fair and consistent terms.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,658.50
#1 3,91,475.50
34.69
#1 54,729.00
9.71
#1 10,980
-145.00
58.34
6,132.00
1,62,480.00
70.59
9,712.00
18.67
2,191
-99.02
56.91
3,550.50
#3 1,20,791.20
#9 59.48
#8 11,539.40
#9 6.99
#9 1,911
#5 14.85
46.90
1,513.10
1,20,726.90
22.66
28,409.50
7.12
5,291
26,808.33
44.95
1,246.10
1,03,033.10
#1 18.30
33,741.20
16.73
5,725
1.26
43.68
2,479.40
1,01,328.10
54.14
12,744.20
#1 20.90
2,007
-18.14
44.46
994.45
99,209.60
21.50
23,511.00
18.55
4,615
#1 15,20,900.00
46.28
1,957.60
87,039.10
24.17
22,909.50
13.74
3,306
51.64
49.43
5,480.50
65,683.00
28.79
13,458.30
3.70
2,216
15.11
56.59
29,690.00
63,588.50
43.43
6,684.70
9.64
1,414
11.55
36.03

Automatic Screeners on ScanX

Growth Rate
Revenue Growth
6.99 %
Net Income Growth
15.39 %
Cash Flow Change
30.61 %
ROE
4.22 %
ROCE
1.42 %
EBITDA Margin (Avg.)
2.17 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
1,234
1,961
1,728
1,573
1,501
1,539
1,449
1,463
1,485
1,453
1,467
1,508
1,708
1,861
1,868
1,951
1,839
1,996
2,002
1,977
1,927
2,018
1,991
1,980
1,954
2,160
2,154
2,142
2,160
2,322
2,277
2,449
2,461
2,582
2,654
2,746
2,726
2,839
2,815
2,795
2,891
3,091
Expenses
992
1,035
976
1,118
1,016
1,114
1,099
1,127
1,139
1,077
1,088
1,104
1,344
1,395
1,421
1,490
1,740
1,481
1,464
1,426
1,398
1,395
1,382
1,388
1,355
1,457
1,477
1,570
2,055
1,635
1,612
1,767
1,764
1,800
1,835
1,863
1,862
1,955
1,950
1,895
2,019
2,146
EBITDA
242
926
752
455
485
425
350
336
346
376
379
404
364
466
447
461
99
515
538
551
529
623
609
592
599
703
677
572
105
687
665
682
697
782
819
883
864
884
865
900
872
945
Operating Profit %
13 %
45 %
41 %
26 %
31 %
26 %
22 %
20 %
18 %
20 %
22 %
23 %
19 %
24 %
24 %
24 %
5 %
25 %
26 %
26 %
27 %
31 %
30 %
30 %
29 %
31 %
30 %
25 %
2 %
29 %
29 %
28 %
28 %
29 %
30 %
31 %
31 %
31 %
31 %
31 %
31 %
31 %
Depreciation
60
57
59
59
63
68
69
73
97
80
84
94
151
150
152
156
160
160
163
163
168
161
165
167
165
165
168
167
162
155
163
193
196
191
201
213
203
197
198
199
201
201
Interest
47
55
48
43
38
49
51
48
58
56
51
80
121
122
126
133
123
122
116
111
102
102
92
91
73
68
71
62
57
55
69
102
107
103
91
80
80
75
64
57
56
56
Profit Before Tax
155
875
681
377
410
346
253
245
244
266
272
259
134
232
205
275
-150
279
296
319
293
402
384
357
383
484
472
357
-87
532
463
419
433
531
559
631
631
656
661
691
665
738
Tax
25
225
172
87
126
54
46
16
38
78
68
201
-94
69
26
29
2
63
52
68
-21
81
74
60
59
154
156
108
31
178
151
127
146
153
173
188
182
199
208
188
167
190
Net Profit
130
650
509
290
284
292
207
229
206
188
204
58
228
163
179
246
-152
216
244
251
314
321
310
297
324
330
316
249
-118
354
312
292
287
378
386
443
449
457
453
503
498
548
EPS in ₹
7.70
38.40
30.01
17.19
16.82
17.28
12.25
13.47
12.17
11.08
12.07
3.37
13.55
9.66
10.57
14.50
-8.95
12.74
14.48
14.77
18.56
18.98
18.32
17.52
19.16
19.53
18.63
14.75
-6.97
20.90
9.22
8.63
8.48
11.18
11.39
13.10
13.27
13.51
13.37
14.88
14.71
16.19

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
7,904
9,058
9,702
14,243
14,121
14,010
14,075
13,100
15,012
15,061
14,990
Fixed Assets
2,833
2,859
3,688
7,855
7,748
7,533
7,065
6,423
8,122
8,138
7,947
Current Assets
4,051
4,688
4,880
5,262
5,038
4,979
5,522
5,165
5,314
5,612
5,623
Capital Work in Progress
678
1,042
520
647
617
712
889
630
765
361
478
Investments
298
780
804
492
353
2
181
226
199
173
156
Other Assets
4,095
4,378
4,691
5,249
5,403
5,763
5,940
5,821
5,926
6,389
6,409
Total Liabilities
7,904
9,058
9,702
14,243
14,121
14,010
14,075
13,100
15,012
15,061
14,990
Current Liabilities
2,824
3,286
2,738
5,202
5,165
5,454
4,892
4,415
5,447
5,425
4,717
Non Current Liabilities
2,589
2,278
2,613
4,418
4,231
3,732
3,346
2,732
3,367
2,779
2,682
Total Equity
2,491
3,495
4,351
4,623
4,724
4,823
5,837
5,953
6,198
6,856
7,591
Reserve & Surplus
2,406
3,410
4,266
4,538
4,640
4,739
5,753
5,868
6,029
6,687
7,422
Share Capital
85
85
85
85
85
85
85
85
169
169
169

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-90
438
18
-366
238
73
-89
-174
110
327
-262
Investing Activities
-2,113
-870
-798
-4,677
-246
229
-444
-196
-2,335
-160
-549
Operating Activities
810
2,742
1,009
894
1,798
1,393
2,005
1,803
2,368
3,266
2,585
Financing Activities
1,212
-1,435
-193
3,417
-1,314
-1,549
-1,651
-1,781
77
-2,780
-2,298

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Jul 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
71.25 %
71.25 %
71.25 %
71.25 %
71.25 %
71.25 %
71.25 %
71.25 %
71.25 %
71.25 %
71.25 %
71.25 %
71.25 %
71.25 %
71.25 %
71.25 %
68.31 %
68.31 %
68.31 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
14.14 %
14.22 %
14.46 %
16.17 %
16.31 %
16.09 %
DIIs
6.53 %
6.71 %
6.76 %
6.78 %
7.52 %
7.82 %
7.76 %
8.89 %
8.87 %
9.00 %
8.31 %
7.16 %
6.44 %
7.26 %
7.27 %
7.08 %
8.35 %
8.35 %
8.65 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
7.89 %
7.72 %
7.58 %
7.29 %
7.25 %
7.10 %
7.13 %
4.59 %
4.73 %
4.47 %
4.38 %
4.25 %
4.15 %
4.09 %
3.98 %
4.34 %
4.61 %
4.51 %
4.44 %
Others
14.33 %
14.33 %
14.42 %
14.68 %
13.98 %
13.83 %
13.86 %
15.27 %
15.16 %
15.28 %
16.07 %
17.34 %
18.16 %
3.27 %
3.28 %
2.87 %
2.56 %
2.52 %
2.50 %
No of Share Holders
0
72,616
64,525
64,309
67,205
63,229
62,933
64,557
67,866
63,831
61,572
69,612
69,117
71,154
74,765
79,848
85,035
86,005
81,856

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 14 14 17 32 35 48 22 28 32
Dividend Yield (%) 0.00 2.24 1.44 1.72 2.51 2.51 3.12 0.85 0.87 0.9

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
16 Feb 2021 DIVIDEND Dividend
₹ 20.00 /share
15 Feb 2021 1,376.03 1,303.15
18 Jun 2021 DIVIDEND Dividend
₹ 15.00 /share
17 Jun 2021 1,382.38 1,476.95
03 Feb 2022 DIVIDEND Dividend
₹ 25.00 /share
02 Feb 2022 1,552.43 1,367.98
06 Jun 2022 DIVIDEND Dividend
₹ 15.00 /share
03 Jun 2022 1,296.25 1,390.33
06 Jun 2022 DIVIDEND Dividend
₹ 8.00 /share
03 Jun 2022 1,296.25 1,390.33
11 Jul 2022 BONUS Bonus
1:1
08 Jul 2022 1,441.88 1,466.70
03 Feb 2023 DIVIDEND Dividend
₹ 14.00 /share
03 Feb 2023 1,584.65 1,541.05
23 Jun 2023 DIVIDEND Dividend
₹ 8.00 /share
23 Jun 2023 1,705.95 1,862.65
12 Feb 2024 DIVIDEND Dividend
₹ 22.00 /share
12 Feb 2024 2,512.50 2,657.35
21 Jun 2024 DIVIDEND Dividend
₹ 6.00 /share
21 Jun 2024 2,691.80 2,858.10
23 Jul 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
23 Jul 2024 2,840.45 3,028.80
25 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
25 Oct 2024 3,557.25 3,317.25
24 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
24 Jan 2025 3,274.45 3,266.20
01 Feb 2025 DIVIDEND Dividend
₹ 26.00 /share
31 Jan 2025 3,266.20 3,259.20
20 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
20 May 2025 3,237.70 3,302.80
20 Jun 2025 DIVIDEND Dividend
₹ 6.00 /share
20 Jun 2025 3,302.80 3,164.00
28 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Jul 2025 3,521.85 3,603.80
28 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
28 Jul 2025 3,334.10 3,603.80

Announcements

Announcement under Regulation 30 (LODR)-Credit Rating2 days ago
Announcement under Regulation 30 (LODR)-Credit Rating2 days ago
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 20155 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication6 days ago
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 20159 days ago
Closure of Trading Window10 days ago
Redemption Of Commercial Papers Issued Under ISIN INE685A14153Sep 26, 2025
Intimation Regarding Issue Of Commercial PapersSep 24, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionSep 23, 2025
Redemption Of Commercial Papers Issued Under ISIN: INE685A14146Sep 18, 2025
Intimation Regarding Issue Of Commercial PapersSep 17, 2025
Announcement under Regulation 30 (LODR)-AcquisitionSep 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 09, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 05, 2025
Announcement Under Reg 30Aug 02, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJul 31, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportJul 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 28, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 28, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 28, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 28, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMJul 28, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 28, 2025
Board Meeting Outcome for Outcome Of Board Meeting Dated 28-Jul-25Jul 28, 2025
Results For Quarter Ended 30-Jun-25Jul 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 21, 2025
Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 21, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations) Letter To Shareholders - Integrated Annual Report FY 2024-25Jul 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 05, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jul 04, 2025
Reg. 34 (1) Annual Report.Jul 04, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionJul 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 01, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJun 30, 2025
Closure of Trading WindowJun 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 30, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJun 29, 2025
Board Meeting Outcome for Disclosure Pursuant To Regulation 30 Read With Schedule III And Regulation 51 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (Listing Regulations).Jun 29, 2025
Redemption Of Commercial Paper Issued Under ISIN INE685A14120Jun 27, 2025
Intimation Regarding Issue Of Commercial PapersJun 26, 2025
Redemption Of Commercial Paper Issued Under ISIN INE685A14138Jun 23, 2025
Announcement under Regulation 30 (LODR)-Issue of SecuritiesJun 20, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jun 09, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 29, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 23, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 21, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 20, 2025
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015May 20, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateMay 20, 2025
Intimation Of Record Date For The Purpose Of Payment Of Final Dividend For FY 2024-25May 20, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Axis Large Cap Fund Direct-Growth
0.00%
-946972
-1.02%
-0.90%
Franklin India Large Cap Fund Direct-Growth
0.00%
-846654
-3.92%
-4.08%
Kotak Small Cap Fund Direct-Growth
0.00%
-463748
-0.94%
-0.97%
Kotak Arbitrage Fund Direct-Growth
0.00%
-416250
-0.21%
-0.07%
Canara Robeco Large Cap Fund Direct-Growth
0.00%
-407164
-0.89%
-0.80%
SBI Healthcare Opportunities Fund Direct Plan-Growth
0.00%
-400000
-3.59%
-2.97%
HDFC Large Cap Fund Direct-Growth
2.84%
395490
0.36%
0.27%
ICICI Prudential Nifty Next 50 Index Direct-Growth
0.00%
-351595
-1.64%
-1.69%
HDFC Large and Mid Cap Fund Direct- Growth
0.00%
-336766
-0.46%
-0.48%
Axis ELSS Tax Saver Direct Plan-Growth
0.00%
-330930
-0.34%
-0.35%
Nippon India Value Fund Direct-Growth
0.00%
-328626
-1.36%
-1.40%
Axis Large & Mid Cap Fund Direct-Growth
0.00%
-312176
-0.76%
-0.79%
Nippon India Pharma Fund Direct-Growth
0.00%
-303364
-1.29%
-1.30%
NJ Balanced Advantage Fund Direct - Growth
0.00%
-236473
-2.17%
-2.29%
Nippon India Arbitrage Fund Direct-Growth
0.00%
-227000
-0.52%
-0.55%
NJ Flexi Cap Fund Direct - Growth
0.00%
-221918
-3.29%
-3.44%
Mirae Asset Healthcare Fund Direct - Growth
0.00%
-215716
-2.75%
-2.78%
Aditya Birla Sun Life Consumption Direct Fund-Growth
0.00%
-203237
-1.14%
-1.22%
Aditya Birla Sun Life Value Direct Fund-Growth
0.00%
-176902
-1.07%
-1.09%
Tata Aggressive Hybrid Fund Direct-Growth
0.00%
-176100
-1.56%
-0.53%
Axis India Manufacturing Fund Direct-Growth
0.00%
-174235
-1.19%
-1.22%
Aditya Birla Sun Life Multi Asset Allocation Fund Direct-Growth
0.00%
-172131
-1.38%
-1.47%
Kotak Large Cap Fund Direct-Growth
0.00%
-170025
-0.59%
-0.61%
Tata India Pharma & Healthcare Fund Direct-Growth
0.00%
-168394
-4.58%
-4.32%
HDFC Manufacturing Fund Direct - Growth
0.00%
-160000
-0.49%
-0.51%

Technical Indicators

RSI(14)
Neutral
49.24
ATR(14)
Less Volatile
71.78
STOCH(9,6)
Neutral
36.24
STOCH RSI(14)
Neutral
22.83
MACD(12,26)
Bearish
-5.23
ADX(14)
Weak Trend
15.39
UO(9)
Bearish
52.88
ROC(12)
Downtrend And Accelerating
-1.66
WillR(14)
Neutral
-57.73

About Torrent Pharmaceuticals

Torrent Pharmaceuticals Limited is a leading Indian pharmaceutical company with a global presence. It specializes in cardiovascular, central nervous system, vitamins and nutrients, gastro-intestinal, and anti-diabetes therapies. The company operates through wholly-owned subsidiaries in over 40 countries, with major operations in the US, Germany, and Brazil. Torrent Pharmaceuticals has manufacturing facilities in multiple Indian states and an R&D center in Ahmedabad. Founded in 1959, the company has grown through acquisitions, expansions, and product launches. It has entered various therapeutic segments including dermatology, gynecology, and oncology. Torrent Pharmaceuticals is engaged in research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations both domestically and internationally.
Chairperson NameSamir Mehta